Currently approved anticoagulants for treating DVT work either by inhibiting factor Xa (FXa) to indirectly reduce thrombin production [12] (e.g., apixaban or rivaroxaban) or directly inhibiting thrombin activity (e.g., dabigatran), thereby blocking the coagulation cascade and inhibiting clot formation. This evidence concerns the gene F10 and deep vein thrombosis.